Progress in the development of new therapies for herpesvirus infections
about
Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantationCuring a viral infection by targeting the host: the example of cyclophilin inhibitorsCurrent and potential treatments for ubiquitous but neglected herpesvirus infectionsA cutting-edge view on the current state of antiviral drug development.Update on emerging antivirals for the management of herpes simplex virus infections: a patenting perspective.The Emerging Roles of Viroporins in ER Stress Response and Autophagy Induction during Virus InfectionHerpes simplex viruses: mechanisms of DNA replication.Ebola Virus Infection: Overview and Update on Prevention and Treatment.The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89.A herpes simplex virus scaffold peptide that binds the portal vertex inhibits early steps in viral replication.Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses.Cytomegalovirus pneumonia in hematopoietic stem cell recipients.Cytomegalovirus infection and the gastrointestinal tract.Cytomegalovirus infection in liver transplant recipients: updates on clinical managementHelicase-primase as a target of new therapies for herpes simplex virus infections.Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions.Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase.The human cytomegalovirus chemokine receptor homolog encoded by US27.The Interaction between Cyclin B1 and Cytomegalovirus Protein Kinase pUL97 is Determined by an Active Kinase DomainThe Interplay of Viral and Host Factors in Chikungunya Virus Infection: Targets for Antiviral Strategies
P2860
Q26826856-209A0F38-AAFC-44D5-A53C-FABD1CB2025CQ26828727-1D25E632-0425-4CA9-8CD6-45DE585B45A3Q27023452-B2A76E12-4ECD-42E1-9720-BF7C2B06CC65Q34036018-3BF05EAC-57D1-49DB-8F2C-89B3D640EA7BQ35531731-9DABAF9D-CA0D-4201-B925-BA1EC2AE4894Q35808638-03029A6E-7C28-4DB8-9C7D-6BF01FDA496EQ36192926-79CA5239-FEB4-49E4-B175-FAFC25B5F6BAQ36363253-04BEFF7B-CDDE-4F2A-B948-60BF0447CEE2Q36559969-FCAAA037-98C1-47EA-A6B4-67B88F9183DEQ36911715-C99A995A-3834-4A9D-B3B1-357C187C0968Q36969798-BE0432F4-6103-445A-90B0-4A59E7F49D4EQ37036545-364540F8-238D-4258-920E-409B2BE0B706Q37179131-15CF1803-B4E4-4637-AA14-6A3FF875D4EEQ38010341-FEB7838F-4F7B-4E0C-B6CA-2F8A7FCE1213Q38242802-E10D423D-5E9E-4738-84B2-2152E1C3E4BEQ38351481-2BC49F46-6F1A-4C6A-B648-B469816EF0A3Q39074863-EE3A8F49-B5A6-48D2-8016-20A632A7251FQ39187112-4FD1FA9E-8435-4122-9B83-7A3903B6491FQ39265988-193B84CD-C1A0-4507-A497-4C8747E391F8Q41485874-6EBD5C6C-89A3-4870-B11F-BE0BDD38CB1BQ56988192-B30BCA98-CDF7-4A6D-BECD-DB3EA33CD360
P2860
Progress in the development of new therapies for herpesvirus infections
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Progress in the development of new therapies for herpesvirus infections
@ast
Progress in the development of new therapies for herpesvirus infections
@en
type
label
Progress in the development of new therapies for herpesvirus infections
@ast
Progress in the development of new therapies for herpesvirus infections
@en
prefLabel
Progress in the development of new therapies for herpesvirus infections
@ast
Progress in the development of new therapies for herpesvirus infections
@en
P2860
P1476
Progress in the development of new therapies for herpesvirus infections
@en
P2093
Mark N Prichard
Nathan B Price
P2860
P304
P356
10.1016/J.COVIRO.2011.10.015
P577
2011-12-01T00:00:00Z